Trials / Recruiting
RecruitingNCT07275840
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center) · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI302 8mg dose | 8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks. |
Timeline
- Start date
- 2025-12-05
- Primary completion
- 2026-08-30
- Completion
- 2026-08-30
- First posted
- 2025-12-10
- Last updated
- 2026-01-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07275840. Inclusion in this directory is not an endorsement.